Menu

ISTOCK, SEZERYADIGAR

Arrests, Investigations Over Vaccine Scandal in China

Changsheng is found to have forged records for a rabies vaccine and is accused of distributing thousands of substandard DPT immunizations to be used in children.

Jul 27, 2018
Kerry Grens

Vaccine maker Changsheng fudged documentation on the quality of materials used in its rabies vaccine and violated the law, a Chinese government investigation has found. The conclusion comes as 15 people, including the chair of the company, are arrested on “suspicion of criminal offences,” Al Jazeera reports.

“The company used expired materials to produce some rabies vaccine and falsified the production date,” according to a government investigation cited by Reuters. “To cover up violations, the company systematically fabricated production and testing records.”

The fallout from the falsified records on the rabies vaccines comes amid news about another serious lapse by Changsheng in which it allegedly sold more than 250,000 doses of an ineffective diphtheria, pertussis, and tetanus (DPT) vaccine.

Problems emerged with Changsheng’s products last year, when China’s regulatory authority found the DPT vaccine to be subpar. Then this summer, Changsheng voluntarily recalled its rabies vaccine after admitting to falsifying records.

Together, the scandals have sown distrust among parents. “We always say that kids are the nation’s future, but if we can’t ensure the safety of such a future, what does the future hold for us?” Huo Xiaoling, whose 1-year-old daughter received a vaccine made by Changsheng, tells The New York Times. She adds that she won’t buy any more Chinese-made vaccines.

The Times notes that there is no evidence anyone has been hurt by the DPT vaccines.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!